Pharmacokinetics of Nucleic-Acid-Based Therapeutics

Handbook of Pharmaceutical Biotechnology

Volumn , Issue , 2006, Pages 1061-1086

  Schmitz, John C ^a,e   Pandyra, Aleksandra ^b,c   Koropatnick, James ^b,c,d   Berg, Randal W ^b,c,d  

^a 3VA Connecticut Healthcare System   (United States)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e YALE CANCER CENTER   (United States)

Author keywords

Cationic molecule polyethylenimine (PEI); Nucleic acid based therapeutics; Pharmacokinetics of nucleic acid based therapeutics

Indexed keywords

EID: 57749170270     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470117118.ch07d     Document Type: Chapter

References (167)

1. Wilton S D, Fletcher S (2005). RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes. Curr. Gene Ther. 5:467-483.
2. Kole R, Vacek M, Williams T (2004). Modification of alternative splicing by antisense therapeutics. Oligonucleotides. 14:65-74.
3. Sazani P, Kole R (2003). Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J. Clin. Invest. 112:481-486.
4. Edelstein M L, Abedi M R, Wixon J, Edelstein R M (2004). Gene therapy clinical trials worldwide 1989-2004-an overview. J. Gene Med. 6:597-602.
5. Shah P B, Losordo D W (2005). Non-viral vectors for gene therapy: Clinical trials in cardiovascular disease. Adv. Genet. 54:339-361.
6. Nishikawa M, Takakura Y, Hashida M (2005). Pharmacokinetics of plasmid DNAbased non-viral gene medicine. Adv. Genet. 53PA:47-68.
7. Lee P A, Blatt L M, et al. (2000). Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatol. 32:640-646.
8. Schubert S, Kurreck J (2004). Ribozyme-and deoxyribozyme-strategies for medical applications. Curr. Drug Targets. 5:667-681.
9. Parry T J, Bouhana K S, Blanchard K S, et al. (2000). Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens. Curr. Issues Mol. Biol. 2:113-118.
10. Sandberg J A, Parker V P, et al. (2000). Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J. Clin. Pharmacol. 40:1462-1469.
11. Kobayashi H, Eckhardt S G, et al. (2005). Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 56:329-336.
12. Weng D E, Masci P A, et al. (2005). A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol. Cancer Ther. 4:948-955.
13. Amantana A, Iversen P L (2005). Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr. Opin. Pharmacol. 5:550-555.
14. Devi G R, Beer T M, et al. (2005). In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin. Cancer Res. 11:3930-3938.
15. Arora V, Devi G R, Iversen P L (2004). Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr. Pharm. Biotechnol. 5:431-439.
16. Jepsen J S, Sorensen M D, Wengel J (2004). Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides. 14:130-146.
17. Fluiter K, ten Asbroek A L, et al. (2003). In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res. 31:953-962.
18. Wahlestedt C, Salmi P, et al. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. U.S.A. 97:5633-5638.
19. McMahon B M, Mays D, et al. (2002). Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev. 12:65-70.
20. Kristensen E (2002). In vitro and in vivo studies on the pharmacokinetics and metabolism of PNA constructs in rodents. Methods Mol. Biol. 208:259-269.
21. Crooke S T (2004). Antisense strategies. Curr. Mol. Med. 4:465-487.
22. Kurreck J (2003). Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270:1628-1644.
23. Giles R V, Spiller D G, Tidd D M (1993). Chimeric oligodeoxynucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificity. Anticancer Drug Des. 8:33-51.
24. ten Asbroek A L, van Groenigen M, Nooij M, Baas F (2002). The involvement of human ribonucleases H1 and H2 in the variation of response of cells to antisense phosphorothioate oligonucleotides. Eur. J. Biochem. 269:583-592.
25. Zamaratski E, Pradeepkumar P I, Chattopadhyaya J (2001). A critical survey of the structure-function of the antisense oligo/RNA heteroduplex as substrate for RNase H. J. Biochem. Biophys. Meth. 48:189-208.
26. Stein C A, Cohen J S (1988). Oligodeoxynucleotides as inhibitors of gene expression: A review. Cancer Res. 48:2659-2668.
27. Achenbach T V, Brunner B, Heermeier K (2003). Oligonucleotide-based knockdown technologies: Antisense versus RNA interference. Chembiochem. 4:928-935.
28. Scanlon K J (2004). Anti-genes: siRNA, ribozymes and antisense. Curr. Pharm. Biotechnol. 5:415-420.
29. Grunweller A, Wyszko E, et al. (2003). Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 31:3185-3193.
30. Micklefield J (2001). Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. Curr. Med. Chem. 8:1157-1179.
31. Geary R S, Watanabe T A, et al. (2001). Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296:890-897.
32. Geary R S, Yu R Z, Levin A A (2001). Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Investig. Drugs. 2:562-573.
33. Agrawal S (1999). Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim. Biophys. Acta. 1489:53-68.
34. Yu R Z, Geary R S, et al. (2004). Tissue disposition of 2′-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J. Pharm. Sci. 93:48-59.
35. Zellweger T, Miyake H, et al. (2001). Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J. Pharmacol. Exp. Ther. 298:934-940.
36. Tolcher A W, Chi K, et al. (2005). A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 11:3854-3861.
37. Marcucci G, Stock W, et al. (2005). Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol. 23:3404-3411.
38. Tolcher A W, Kuhn J, et al. (2004). A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 10:5048-5057.
39. Rudin C M, Kozloff M, et al. (2004). Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J. Clin. Oncol. 22:1110-1117.
40. Morris M J, Tong W P, et al. (2002). Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 8:679-683.
41. Desai A A, Schilsky R L, et al. (2005). A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann. Oncol. 16:958-965.
42. Bishop M R, Iversen P L, et al. (1996). Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol. 14:1320-1326.
43. Bayever E, Iversen P L, et al. (1993). Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res. Dev. 3:383-390.
44. Stewart D J, Donehower R C, et al. (2003). A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann. Oncol. 14:766-774.
45. Sereni D, Tubiana R, et al. (1999). Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIVpositive subjects. J. Clin. Pharmacol. 39:47-54.
46. Zhang R, Yan J, et al. (1995). Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther. 58:44-53.
47. Tolcher A W, Reyno L, et al. (2002). A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 8:2530-2535.
48. Rudin C M, Holmlund J, et al. (2001). Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin. Cancer Res. 7:1214-1220.
49. Stevenson J P, Yao K S, et al. (1999). Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol. 17:2227-2236.
50. Adjei A A, Dy G K, et al. (2003). A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin. Cancer Res. 9:115-123.
51. Cunningham C C, Holmlund J T, et al. (2001). A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer. 92:1265-1271.
52. Kahan B D, Stepkowski S, et al. (2004). Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection. Transplan. 78:858-863.
53. Yacyshyn B R, Barish C, et al. (2002). Dose ranging pharmacokinetic trial of highdose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment. Pharmacol. Ther. 16:1761-1770.
54. Glover J M, Leeds J M, et al. (1997). Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther. 282:1173-1180.
55. Marshall J L, Eisenberg S G, et al. (2004). A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clin. Colorectal Cancer. 4:268-274.
56. Mani S, Rudin C M, et al. (2002). Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin. Cancer Res. 8:1042-1048.
57. Villalona-Calero M A, Ritch P, et al. (2004). A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 10:6086-6093.
58. Goel S, Desai K, et al. (2003). A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. Clin. Cancer Res. 9:4069-4076.
59. Chen H X, Marshall J L, et al. (2000). A safety and pharmacokinetic study of a mixedbackbone oligonucleotide (GEM231) targeting the type I protein kinase A by two hour infusions in patients with refractory solid tumors. Clin. Cancer Res. 6:1259-1266.
60. Sewell K L, Geary R S, et al. (2002). Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J. Pharmacol. Exp. Ther. 303:1334-1343.
61. Chi K N, Eisenhauer E, et al. (2005). A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. 97:1287-1296.
62. Jason T L, Koropatnick J, Berg R W (2004). Toxicology of antisense therapeutics. Toxicol. Appl. Pharmacol. 201:66-83.
63. Krieg A M (1999). Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim. Biophys. Acta. 1489:107-116.
64. Ioannou X P, Gomis S M, et al. (2002). CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine. 21:127-137.
65. Levin A A (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta. 1489:69-84.
66. Shaw D R, Rustagi P K, et al. (1997). Effects of synthetic oligonucleotides on human complement and coagulation. Biochem. Pharmacol. 53:1123-1132.
67. Gleave M E, Monia B P (2005). Antisense therapy for cancer. Nat. Rev. Cancer. 5:468-479.
68. Fluiter K, Frieden M, et al. (2005). On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Chembiochem. 6:1104-1109.
69. Jepsen J S, Wengel J (2004). LNA-antisense rivals siRNA for gene silencing. Curr. Opin. Drug Discov. Devel. 7:188-194.
70. Vester B, Wengel J (2004). LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochem. 43:13233-13241.
71. Frieden M, Christensen S M, et al. (2003). Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res. 31:6365-6372.
72. Lok C N, Viazovkina E, et al. (2002). Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2′-deoxy-2′-fluoro-Darabinose and 2′-deoxyribose nucleotides. Biochem. 41:3457-3467.
73. Mangos M M, Min K L, et al. (2003). Efficient RNase H-directed cleavage of RNA promoted by antisense DNA or 2′F-ANA constructs containing acyclic nucleotide inserts. J. Am. Chem. Soc. 125:654-661.
74. Wilds C J, Damha M J (2000). 2′-Deoxy-2′-fluoro-beta-D-arabinonucleosides and oligonucleotides (2′F-ANA): synthesis and physicochemical studies. Nucleic Acids Res. 28:3625-3635.
75. Kaihatsu K, Huffman K E, Corey D R (2004). Intracellular uptake and inhibition of gene expression by PNAs and PNA-peptide conjugates. Biochem. 43:14340-14347.
76. Nielsen P E (2005). Gene targeting using peptide nucleic acid. Methods Mol. Biol. 288:343-358.
77. Marin V L, Roy S, Armitage B A (2004). Recent advances in the development of peptide nucleic acid as a gene-targeted drug. Expert. Opin. Biol. Ther. 4:337-348.
78. Foubister V (2003). New PNA tool makes great antisense. Drug Discov. Today. 8:520-521.
79. Koppelhus U, Nielsen P E (2003). Cellular delivery of peptide nucleic acid (PNA). Adv. Drug Deliv. Rev. 55:267-280.
80. Stephens A C (2004). Technology evaluation: AVI-4126, AVI BioPharma. Curr. Opin. Mol. Ther. 6:551-558.
81. Pannier A K, Arora V, Iversen P L, et al. (2004). Transdermal delivery of phosphorodiamidate Morpholino oligomers across hairless mouse skin. Int. J. Pharm. 275:217-226.
82. Iversen P L (2001). Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr. Opin. Mol. Ther. 3:235-238.
83. Iversen P L, Arora V, Acker A J, et al. (2003). Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin. Cancer Res. 9:2510-2519.
84. Berg R W, Werner M, et al. (2001). Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase. J. Pharmacol. Exp. Ther. 298:477-484.
85. Kuhnast B, Dolle F, et al. (2000). General method to label antisense oligonu-cleotides with radioactive halogens for pharmacological and imaging studies. Bioconjug. Chem. 11:627-636.
86. Yu R Z, Geary R S, Levin A A (2004). Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic/pharmacodynamic assessments of antisense oligonucleotides. Curr. Opin. Drug Discov. Devel. 7:195-203.
87. Gilar M, Fountain K J, et al. (2003). Characterization of therapeutic oligonucleotides using liquid chromatography with on-line mass spectrometry detection. Oligonucleotides. 13:229-243.
88. Freudemann T, von Brocke A, Bayer E (2001). On-line coupling of capillary gel electrophoresis with electrospray mass spectrometry for oligonucleotide analysis. Anal. Chem. 73:2587-2593.
89. de Serres M, McNulty M J, Christensen L, et al. (1996). Development of a novel scintillation proximity competitive hybridization assay for the determination of phosphorothioate antisense oligonucleotide plasma concentrations in a toxicokinetic study. Anal. Biochem. 233:228-233.
90. Brown-Augsburger P, Yue X M, et al. (2004). Development and validation of a sensitive, specific, and rapid hybridization-ELISA assay for determination of concentrations of a ribozyme in biological matrices. J. Pharm. Biomed. Anal. 34:129-139.
91. Brand R M (2001). Topical and transdermal delivery of antisense oligonucleotides. Curr. Opin. Mol. Ther. 3:244-248.
92. Brand R M, Iversen P L (2005). Transdermal delivery of antisense oligonucleotides. Methods Mol. Med. 106:255-269.
93. White P J, Atley L M, Wraight C J (2004). Antisense oligonucleotide treatments for psoriasis. Expert. Opin. Biol. Ther. 4:75-81.
94. Dokka S, Cooper S R, Kelly S, et al. (2005). Dermal delivery of topically applied oligonucleotides via follicular transport in mouse skin. J. Invest Dermatol. 124:971-975.
95. White P J, Gray A C, et al. (2002). C-5 propyne-modified oligonucleotides penetrate the epidermis in psoriatic and not normal human skin after topical application. J. Invest Dermatol. 118:1003-1007.
96. Ramakumar S, Phull H, et al. (2005). Novel delivery of oligonucleotides using a topical hydrogel tissue sealant in a murine partial nephrectomy model. J. Urol. 174:1133-1136.
97. Bochot A, Couvreur P, Fattal E (2000). Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog. Retin. Eye Res. 19:131-147.
98. Klimuk S K, Semple S C, et al. (2000). Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity. J. Pharmacol. Exp. Ther. 292:480-488.
99. Tezel A, Dokka S, Kelly S, Hardee G E, Mitragotri S (2004). Topical delivery of anti-sense oligonucleotides using low-frequency sonophoresis. Pharm. Res. 21:2219-2225.
100. Regnier V, Preat V (1998). Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation. Pharm. Res. 15:1596-1602.
101. Sandrasagra A, Leonard S A, et al. (2002). Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. 12:177-181.
102. Nyce J (2002). Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease. Curr. Opin. Allergy Clin. Immunol. 2:533-536.
103. Ball H A, Van Scott M R, Robinson C B (2004). Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders. Clin. Rev. Allergy Immunol. 27:207-217.
104. Ball H A, Sandrasagra A, et al. (2003). Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma. Am. J. Pharmacogenom. 3:97-106.
105. Ali S, Leonard S A, et al. (2001). Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. Am. J. Respir. Crit. Care Med. 163:989-993.
106. Templin M V, Levin A A, et al. (2000). Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev. 10:359-368.
107. Geary R S, Khatsenko O, et al. (2001). Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther. 296:898-904.
108. Raoof A A, Chiu P, et al. (2004). Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J. Pharm. Sci. 93:1431-1439.
109. Agrawal S, Zhang X, et al. (1995). Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol. 50:571-576.
110. Raoof A A, Ramtoola Z, et al. (2002). Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur. J. Pharm. Sci. 17:131-138.
111. Yu R Z, Geary R S, et al. (1999). Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes. Pharm. Res. 16:1309-1315.
112. Miyano-Kurosaki N, Barnor J S, et al. (2004). In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes. Antivir. Chem. Chemother. 15:93-100.
113. Yoshida J, Mizuno M (2003). Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma. J. Neurooncol. 65:261-267.
114. Rudin C M, Marshall J L, et al. (2004). Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: A phase I study. Clin. Cancer Res. 10:7244-7251.
115. Springate C M, Jackson J K, Gleave M E, et al. (2005). Efficacy of an intra tumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemother. Pharmacol. 56:239-247.
116. Agrawal S, Temsamani J, Tang J Y (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. U.S.A. 88:7595-7599.
117. Dvorchik B H (2000). The disposition (ADME) of antisense oligonucleotides. Curr. Opin. Mol. Ther. 2:253-257.
118. Saijo Y, Perlaky L, Wang H, et al. (1994). Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol. Res. 6:243-249.
119. Geary R S, Henry S P, Grillone L R (2002). Fomivirsen: clinical pharmacology and potential drug interactions. Clin. Pharmacokinet. 41:255-260.
120. Cotter F E, Waters J, Cunningham D (1999). Human Bcl-2 antisense therapy for lymphomas. Biochim. Biophys. Acta. 1489:97-106.
121. Raynaud F I, Orr R M, et al. (1997). Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous adminis-tration or continuous subcutaneous infusion to mice. J. Pharmacol. Exp. Ther. 281:420-427.
122. O'Brien S M, Cunningham C C, et al. (2005). Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J. Clin. Oncol. 23:7697-7702.
123. Lopes de Menezes D E, Mayer L D (2002). Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother. Pharmacol. 49:57-68.
124. Cossum P A, Truong L, et al. (1994). Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269:89-94.
125. Cossum P A, Sasmor H, et al. (1993). Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267:1181-1190.
126. Waters J S, Webb A, et al. (2000). Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 18:1812-1823.
127. Guo S, Kemphues K J (1995). par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell. 81:611-620.
128. Fire A, Xu S, et al. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:806-811.
129. Zamore P D (2001). RNA interference: Listening to the sound of silence. Nat. Struct. Biol. 8:746-750.
130. Sharp P A (2001). RNA interference-2001. Genes Dev. 15:485-490.
131. Bernstein E, Denli A M, Hannon G J (2001). The rest is silence. RNA. 7:1509-1521.
132. Elbashir S M, Martinez J, Patkaniowska A, et al. (2001). Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20:6877-6888.
133. Elbashir S M, Harborth J, et al. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494-498.
134. Lin X, Ruan X, et al. (2005). siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res. 33:4527-4535.
135. Du Q, Thonberg H, Wang J, et al. (2005). A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res. 33:1671-1677.
136. Saxena S, Jonsson Z O, Dutta A (2003). Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J. Biol. Chem. 278:44312-44319.
137. Fedorov Y, King A, et al. (2005). Different delivery methods-different expression profiles. Nat. Methods. 2:241.
138. Muratovska A, Eccles M R (2004). Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 558:63-68.
139. Urban-Klein B, Werth S, Abuharbeid S, et al. (2005). RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12:461-466.
140. Vickers T A, Koo S, et al. (2003). Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem. 278:7108-7118.
141. Verma U N, Surabhi R M, Schmaltieg A, Becerra C, Gaynor R B (2003). Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. 9:1291-1300.
142. Filleur S, Courtin A, et al. (2003). SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 63:3919-3922.
143. Duxbury M S, Ito H, Zinner M J, et al. (2004). RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 23:1539-1548.
144. Morrissey D V, Blanchard K, et al. (2005). Activity of stabilized short inter-fering RNA in a mouse model of hepatitis B virus replication. Hepatol. 41:1349-1356.
145. Lewis D L, Hagstrom J E, Loomis A G, et al. (2002). Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 32:107-108.
146. Song E, Lee S K, et al. (2003). RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9:347-351.
147. Zender L, Hutker S, et al. (2003). Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. U.S.A. 100:7797-7802.
148. Layzer J M, McCaffrey A P, et al. (2004). In vivo activity of nuclease-resistant siRNAs. RNA. 10:766-771.
149. Chiu Y L, Rana T M (2003). siRNA function in RNAi: A chemical modification analysis. RNA. 9:1034-1048.
150. Czauderna F, Fechtner M, et al. (2003). Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31:2705-2716.
151. Harborth J, Elbashir S M, et al. (2003). Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 13:83-105.
152. Soutschek J, Akinc A, et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 432:173-178.
153. Bitko V, Musiyenko A, Shulyayeva O, Barik S (2005). Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11:50-55.
154. Zhang W, Yang H, et al. (2005). Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat. Med. 11:56-62.
155. Zhang X, Shan P, et al. (2004). Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem. 279:10677-10684.
156. Boussif O, Lezoualc'h F, et al. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U.S.A. 92:7297-7301.
157. Chollet P, Favrot M C, Hurbin A, et al. (2002). Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J. Gene Med. 4:84-91.
158. Dufes C, Keith W N, et al. (2005). Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res. 65:8079-8084.
159. Schiffelers R M, Ansari A, et al. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32: e149.
160. Sioud M, Sorensen D R (2003). Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 312:1220-1225.
161. Yano J, Hirabayashi K, et al. (2004). Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 10:7721-7726.
162. Chien P Y, Wang J, et al. (2005). Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther. 12:321-328.
163. Morrissey D V, Lockridge J A, et al. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23:1002-1007.
164. Prenner J L, Thompson J T, Miller D G, et al. (2005). An Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Intravitreous VEGF siRNA (Cand5) in Patients With Wet Age-Related Macular Degeneration. American Academy of Ophthalmology Annual Meeting, poster 463.
165. Quinlan E, Nguyen Q, Kaiser P, et al. (2005). A Phase I, open-label, dose escalation trial of intravitreal injection of small interfering RNA molecule in subjects with neovascular AMD. American Academy of Ophthalmology Annual Meeting. Available: http://www.sirna.com/media/pdfs/AAOSIRNA.pdf.
166. Miyagishi M, Hayashi M, Taira K (2003). Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. 13:1-7.
167. Bertrand J R, Pottier M, et al. (2002). Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 296:1000-1004.